Safe use of platelet GP IIb/IIIa inhibitors

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Ferguson, J J ^a   Kereiakes, D J ^a   Adgey, A A J ^a   Fox, K A A ^a   Hillegass W B , Jr ^a   Pfisterer, M ^a   Vassanelli, C ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FRESH FROZEN PLASMA; HEPARIN; LAMIFIBAN; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ATHERECTOMY; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ACCESS;

EID: 0031960015     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70300-X     Document Type: Article

References (33)

1. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
2. EJ Topol RM Califf HF Weisman Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 343 1994 881 886
3. EJ Topol JJ Ferguson HF Weisman Long-term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention JAMA 278 1997 479 484
4. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
5. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
6. Data on file. Centocor Inc., Malvern, Pa.
7. FV Aguirre EJ Topol JJ Ferguson Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention Circulation 91 1995 2882 2890
8. DJ Moliterno RM Califf FV Aguirre Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) Am J Cardiol 75 1995 559 562
9. AM Lincoff JE Tcheng TA Bass A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody fragment c7E3 Fab during percutaneous coronary revascularization [abstract] J Am Coll Cardiol 25 suppl A 1995 80A 81A
10. J Deckers RM Califf EJ Topol AM Lincoff JE Tcheng ML Simoons Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials [abstract] J Am Coll Cardiol 29 1997 241A
11. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II Lancet 349 1997 1422 1428
12. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
13. DR Phillips W Teng A Arfsten Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494
14. Topol EJ. PURSUIT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997, Stockholm, Sweden.
15. JD Boehrer DJ Kereiakes FI Navetta RM Califf EJ Topol Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery Am J Cardiol 74 1994 1166 1170
16. SD Berkowitz RA Harrington MM Rund JE Tcheng Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy Circulation 95 1997 809 813
17. NS Kleiman EM Ohman RM Califf Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study J Am Coll Cardiol 22 1993 381 389
18. KJ Reddy R Khoshnevis S Simek ReoPro as an adjunct to intracoronary thrombolytic therapy [abstract] J Invas Cardiol 8 1996 66
19. EM Ohman NS Kleiman G Gacioch Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial Circulation 95 1997 846 854
20. Harrington RA. PARADIGM. Presented at the 69th Scientific Sessions of the American Heart Association, November 10-13, 1996; New Orleans, La.
21. Data on file. Eli Lilly and Company. Indianapolis, Ind.
22. JA Ambrose OD Almeida SK Sharma Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: results of the TAUSA trial Circulation 90 1994 69 77
23. The TIMI IIIB Investigators Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial Circulation 89 1994 1545 1556
24. RA Yaryura S Simek J Benrey ReoPro plus stenting: pushing the envelope of clinical applications for stents [abstract] J Invas Cardiol 8 1996 67
25. T Ammar LE Scudder BS Coller In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time Circulation 95 1997 614 617
26. CP Juergens AC Yeung SN Oesterle Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab Am J Cardiol 80 1997 74 75
27. DJ Kereiakes TM Broderick DD Whang L Anderson D Fye Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention Am J Cardiol 80 1997 633 634
28. JC Blankenship AS Helkamp SL Demko FV Aguirre EJ Topol RM Califf Vascular access site complications after percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor therapy in the EPIC trial [abstract] J Am Coll Cardiol 29 1997 278A
29. M Madan DJ Kereiakes M Rund Abciximab readministration for coronary interventions: is it safe? Circulation [abstract] 96 suppl I 1997 I162
30. 3)[abstract] J Am Coll Cardiol 31 1998 55A
31. DJ Kereiakes JH Essell CW Abbottsmith TM Broderick JP Runyon Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion Am J Cardiol 78 1996 1161 1163
32. Data on file. Eli Lilly and Company, Indianapolis, Ind.
33. NS Kleiman MA Mascelli N Graziadei Ticlopidine potentiates abciximab's ability to inhibit ADP-induced platelet aggregation in vitro [abstract] J Am Coll Cardiol 29 2 suppl A 1997 241A